Study of Acid Reflux Therapy for Children with Asthma
儿童哮喘胃酸反流治疗研究
基本信息
- 批准号:7878064
- 负责人:
- 金额:$ 46.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-20 至 2011-06-30
- 项目状态:已结题
- 来源:
- 关键词:16 year oldAcidsAdrenal Cortex HormonesAdverse eventAgonistAsthmaBreathingBronchial SpasmCYP2C19 geneChildClinicalClinical Trials Data Monitoring CommitteesCommunicationCytochrome P450DataData AnalysesData CollectionData Coordinating CenterData QualityDiseaseDocumentationDoseElectronicsEpidemiologyEsophagealFrequenciesGastric AcidGastroesophageal reflux diseaseGenetic PolymorphismGrantHealthcareHourInflammatoryInformed ConsentInterleukin-1 betaInterviewLabelLansoprazoleLeadLeadershipManualsMasksMeasuresMonitorOnline SystemsOutcome MeasureParticipantPathway interactionsPatientsPerformancePharmaceutical PreparationsPlacebosPlasmaProceduresProductionProtocols documentationProton Pump InhibitorsPublicationsRandom AllocationRandomizedRandomized Clinical TrialsRefluxReportingResearch Ethics CommitteesResearch InfrastructureResearch PersonnelRespiratory physiologySeveritiesSiteSubgroupSymptomsSystemTestingTrainingVariantairway inflammationcytokinedata managementdesigndiariesevidence basefollow-upknowledge basemeetingsoperationprimary outcomequality assuranceresponsesecondary outcomesymposiumtreatment responseweb based interfaceweb site
项目摘要
DESCRIPTION (provided by applicant):
Gastroesophageal reflux (GER) is frequent in children with asthma, can induce bronchospasm, and increase airways reactivity. Children with asthma are often treated for GER with drugs to suppress gastric acid production. However, this treatment is expensive, and with unproven benefit. The primary objective in this proposal is to conduct a multi-site, randomized, clinical trial to test the hypothesis that treatment of GER with lansoprazole, an approved proton pump inhibitor, will decrease the frequency of exacerbations in children with poorly controlled asthma. The study will include 300 asthmatic children treated with inhaled corticosteroids, 6-16 years of age, with poor control defined by frequent symptoms, excessive beta agonist use, or frequent exacerbations. Participants will be randomly assigned to treatment with either lansoprazole or placebo for six months. The presence, severity, and relationship of GER to asthma symptoms will be determined with 24 hour esophageal pH monitoring, but randomization to treatment will not be influenced by the presences or severity of GER. The primary outcome measure is the proportion of participants who have exacerbations of asthma defined by diaries and interviews. Secondary outcome measures include asthma symptom and control scores, GER symptoms, lung function, and unscheduled health care contacts. Pre-defined subgroup analyses will examine the relationship between specific clinical features and the response to lansoprazole.
Treatment response will also be evaluated with 3-hour post-dose plasma lansoprazole concentrations, and related to polymorphisms in CYP2C19, the cytochrome P450 pathway, and IL-1 beta, a pro-inflammatory cytokine. Tertiary studies will determine how the magnitude of GER impacts airways inflammation, as measured by the concentrations of H+ (pH) and NO in expired breath.
The results of this trial should have a major impact on the understanding and treatment of GER in children with asthma.
描述(由申请人提供):
哮喘儿童经常出现胃食管反流(GER),可以诱导支气管痉挛并增加气道反应性。患有哮喘的儿童经常用药物治疗GER,以抑制胃酸的产生。但是,这种治疗量昂贵,并且有未经证实的益处。该提案的主要目的是进行多站点,随机的临床试验,以检验以下假设:用兰索拉唑(一种批准的质子泵抑制剂)治疗GER将降低控制不良哮喘的儿童的加重频率。这项研究将包括300名接受吸入皮质类固醇治疗的哮喘儿童,6-16岁,由频繁症状,过度β激动剂使用或频繁恶化的症状定义不良。参与者将被随机分配给兰索拉唑或安慰剂六个月。 GER与哮喘症状的存在,严重程度和关系将通过24小时的食管pH监测确定,但是与治疗的随机分组不会受到GER的存在或严重程度的影响。主要结局措施是日记和访谈定义的哮喘患者加剧的参与者的比例。次要结局指标包括哮喘症状和控制分数,GER症状,肺功能和外科医疗保健接触。预定义的亚组分析将检查特定临床特征与对兰索拉唑的反应之间的关系。
治疗反应还将用剂量后血浆兰索浓度进行评估,并与CYP2C19,细胞色素P450途径和IL-1β(一种促炎性细胞因子)中的多态性有关。第三级研究将确定GER的大小如何影响气道炎症,如H+(pH)的浓度和无呼吸中的无。
该试验的结果应对哮喘儿童的GER的理解和治疗产生重大影响。
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Obesity in children with poorly controlled asthma: Sex differences.
- DOI:10.1002/ppul.22707
- 发表时间:2013-09
- 期刊:
- 影响因子:3.1
- 作者:Lang, Jason E.;Holbrook, Janet T.;Wise, Robert A.;Dixon, Anne E.;Teague, W. Gerald;Wei, Christine Y.;Irvin, Charles G.;Shade, David;Lima, John J.
- 通讯作者:Lima, John J.
Lansoprazole for children with poorly controlled asthma: a randomized controlled trial.
- DOI:10.1001/jama.2011.2035
- 发表时间:2012-01-25
- 期刊:
- 影响因子:120.7
- 作者:Holbrook, Janet T.;Wise, Robert A.;Gold, Benjamin D.;Blake, Kathryn;Brown, Ellen D.;Castro, Mario;Dozor, Allen J.;Lima, John J.;Mastronarde, John G.;Sockrider, Marianna M.;Teague, W. Gerald
- 通讯作者:Teague, W. Gerald
Exhaled breath condensate pH does not discriminate asymptomatic gastroesophageal reflux or the response to lansoprazole treatment in children with poorly controlled asthma.
呼出气冷凝物 pH 值不能区分无症状胃食管反流或哮喘控制不佳的儿童对兰索拉唑治疗的反应。
- DOI:10.1016/j.jaip.2014.04.006
- 发表时间:2014
- 期刊:
- 影响因子:0
- 作者:Fitzpatrick,AnneM;Holbrook,JanetT;Wei,ChristineY;Brown,MeredithS;Wise,RobertA;Teague,WGerald;AmericanLungAssociation'sAsthmaClinicalResearchCentersNetwork
- 通讯作者:AmericanLungAssociation'sAsthmaClinicalResearchCentersNetwork
Reply: worsening asthma control in children taking lansoprazole: possible mechanisms.
答复:服用兰索拉唑的儿童哮喘控制恶化:可能的机制。
- DOI:10.1513/annalsats.201505-298le
- 发表时间:2015
- 期刊:
- 影响因子:8.3
- 作者:Lang,JasonE;Holbrook,JanetT;Lima,JohnJ;AmericanLungAssociation-AsthmaClinicalResearchCenters
- 通讯作者:AmericanLungAssociation-AsthmaClinicalResearchCenters
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Janet T. Holbrook其他文献
THE RELATIONSHIP BETWEEN ASTHMA AND RHINITIS/RHINOSINUSITIS
- DOI:
10.1378/chest.128.4_meetingabstracts.147s-a - 发表时间:
2005-10-01 - 期刊:
- 影响因子:
- 作者:
Anne E. Dixon;David A. Kaminsky;Janet T. Holbrook;Robert A. Wise;David M. Shade;Charles G. Irvin - 通讯作者:
Charles G. Irvin
Janet T. Holbrook的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Janet T. Holbrook', 18)}}的其他基金
ADalimumab Vs. conventional ImmunoSupprEssion for uveitis(ADVISE) Trial
阿达木单抗对比。
- 批准号:
10480091 - 财政年份:2018
- 资助金额:
$ 46.68万 - 项目类别:
ADalimumab Vs. conventional ImmunoSupprEssion for uveitis(ADVISE) Trial
阿达木单抗对比。
- 批准号:
10002234 - 财政年份:2018
- 资助金额:
$ 46.68万 - 项目类别:
Macular Edema Treatment Trials Associated with MUST (META-MUST)
与 MUST 相关的黄斑水肿治疗试验 (META-MUST)
- 批准号:
8996746 - 财政年份:2014
- 资助金额:
$ 46.68万 - 项目类别:
Macular Edema Treatment Trials Associated with MUST (META-MUST)
与 MUST 相关的黄斑水肿治疗试验 (META-MUST)
- 批准号:
9211348 - 财政年份:2014
- 资助金额:
$ 46.68万 - 项目类别:
Macular Edema Treatment Trials Associated with MUST (META-MUST)
与 MUST 相关的黄斑水肿治疗试验 (META-MUST)
- 批准号:
8986226 - 财政年份:2014
- 资助金额:
$ 46.68万 - 项目类别:
Study of Acid Reflux Therapy for Children with Asthma
儿童哮喘胃酸反流治疗研究
- 批准号:
6904865 - 财政年份:2006
- 资助金额:
$ 46.68万 - 项目类别:
Study of Acid Reflux Therapy for Children with Asthma
儿童哮喘胃酸反流治疗研究
- 批准号:
7637446 - 财政年份:2006
- 资助金额:
$ 46.68万 - 项目类别:
Study of Acid Reflux Therapy for Children with Asthma
儿童哮喘胃酸反流治疗研究
- 批准号:
7288749 - 财政年份:2006
- 资助金额:
$ 46.68万 - 项目类别:
相似国自然基金
阿魏酸基天然抗氧化抗炎纳米药物用于急性肾损伤诊疗一体化研究
- 批准号:82302281
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
深层碳酸盐岩酸蚀裂缝中反应-非线性两相流界面演化机制研究
- 批准号:52304047
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
核苷酸代谢酶氧化修饰调控上皮干细胞命运在口腔白斑病光动力治疗复发中的机制与意义研究
- 批准号:82330029
- 批准年份:2023
- 资助金额:220 万元
- 项目类别:重点项目
RNF31通过厚壁菌代谢产物3-氧代胆碱酸调控RORγ信号轴抑制Th17细胞分化—溃疡性结肠炎干预新靶点
- 批准号:82360112
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
氨基酸转运体调控非酒精性脂肪肝的模型建立及机制研究
- 批准号:32371222
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Intra-Articular Drug Delivery Modulating Immune Cells in Inflammatory Joint Disease
关节内药物递送调节炎症性关节疾病中的免疫细胞
- 批准号:
10856753 - 财政年份:2023
- 资助金额:
$ 46.68万 - 项目类别:
An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD
一种吸入性微生物组靶向生物治疗药物,用于治疗慢性阻塞性肺病
- 批准号:
10600887 - 财政年份:2023
- 资助金额:
$ 46.68万 - 项目类别:
IL-27-mediated immunoregulation in HSV-1-induced stromal keratitis
HSV-1 诱导的基质性角膜炎中 IL-27 介导的免疫调节
- 批准号:
10737119 - 财政年份:2023
- 资助金额:
$ 46.68万 - 项目类别:
New target and new therapy for severe Covid-19 and viral hyperinflammation damage: renalase and renalase agonists
严重Covid-19和病毒性过度炎症损伤的新靶点和新疗法:肾酶和肾酶激动剂
- 批准号:
10759030 - 财政年份:2023
- 资助金额:
$ 46.68万 - 项目类别:
An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD
一种吸入性微生物组靶向生物治疗药物,用于治疗慢性阻塞性肺病
- 批准号:
10917559 - 财政年份:2023
- 资助金额:
$ 46.68万 - 项目类别: